ロイタービデオ

次のビジネス (26 ビデオ)

    ビジネス

    CureVac fails in pivotal COVID-19 vaccine trial

    German biotech CureVac NV said on Wednesday its COVID-19 vaccine was only 47% effective in a late-stage trial, missing the study's main goal and throwing in doubt the potential delivery of hundreds of millions of doses to the European Union. Emer McCarthy reports.